/IKING THERAPEUTICS Corporate Presentation April 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ab ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2021 Earnings Conference Call April 28, 2021 4:30 PM ET Company Participants Stephanie Diaz - Manager, Investor Relations Brian Lian - President and Chief Executive Officer Greg Zante - Chief Financial Officer Conference Call Participants Ryan Deschner - Raymond James Michael Morabito - Chardan Capital Markets Ben Porter - Stifel Andy Hsieh - William Blair Jay Olson - Oppenheimer Scott Henry - ROTH Capital Sahil Kazmi - B. Riley FBR Operator Welcome to the Viking T ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. Securities registered pursuant to Section 12(b) of the Act | Title of Each Class | Trading Symbo ...

Corporate Presentation March 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

Corporate Presentation March 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our collaborators' ability to successfull ...

/IKING T H E R A P E U T I C S Corporate Presentation February 2021 Forward-Looking Statements This presentation contains statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks relating to: both our and our col ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2020 Earnings Conference Call February 17, 2021 4:30 PM ET Company Participants Stephanie Diaz – Manager-Investor Relations Brian Lian – President and Chief Executive Officer Greg Zante – Chief Financial Officer Conference Call Participants Derek Archila – Stifel Joon Lee – Truist Securities Michael Morabito – Chardan Capital Markets Matt Luchini – BMO Capital Steve Seedhouse – Raymond James Julian Harrison – BTIG Andy Hsieh – William Blair Yale Jen – Laidlaw & Co. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37355 Viking Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 46-1073877 ( State or other jurisdict ...

Financial Data and Key Metrics Changes - Research and development expenses for Q3 2020 were $7.1 million, up from $5.3 million in Q3 2019, primarily due to increased clinical study expenses, salaries, and stock-based compensation [12] - General and administrative expenses for Q3 2020 were $2.7 million, compared to $2.2 million in Q3 2019, driven by higher stock-based compensation and insurance expenses [13] - Net loss for Q3 2020 was $9.3 million or $0.13 per share, compared to a net loss of $5.7 million or $0.08 per share in Q3 2019 [13] - For the first nine months of 2020, research and development expenses totaled $22.9 million, up from $17.1 million in the same period in 2019 [14] - The net loss for the first nine months of 2020 was $28.5 million or $0.39 per share, compared to a net loss of $18.3 million or $0.25 per share in the same period in 2019 [15] - Cash, cash equivalents, and short-term investments totaled $255.3 million as of September 30, 2020, down from $275.6 million at the end of 2019 [16] Business Line Data and Key Metrics Changes - The lead program VK2809 continued patient enrollment in the Phase 2b VOYAGE study for nonalcoholic steatohepatitis (NASH) and fibrosis, with expectations to complete enrollment in the first half of 2021 [7][22] - VK0214 advanced into clinical development with the initiation of a Phase 1 trial in healthy subjects, with plans for a Phase 1b study in patients with X-linked adrenoleukodystrophy (X-ALD) [9][24] Market Data and Key Metrics Changes - The majority of U.S. clinical sites for VK2809 were open for patient enrollment despite COVID-19 disruptions, with plans to expand internationally [7][22] - The VOYAGE study is targeting approximately 340 patients across five treatment arms, focusing on patients with F2 and F3 fibrosis [21] Company Strategy and Development Direction - The company is focused on executing its two clinical programs, VK2809 for NASH and VK0214 for X-ALD, while managing cash resources carefully to support ongoing trials [25][26] - The strategy includes exploring the potential for intermittent dosing based on the durability of liver fat reduction observed in VK2809 trials [30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in patient enrollment due to COVID-19 but remains optimistic about completing enrollment in the first half of 2021 [35] - The regulatory pathway for VK0214 is expected to involve discussions with the FDA regarding endpoints and registration, with potential data from the Phase 1b study by late 2021 [35][71] Other Important Information - The company plans to open additional clinical sites in Europe imminently, with some delays attributed to administrative issues [45] - Management is preparing a manuscript for the 12-week study results, with intentions to submit it to a journal soon [39] Q&A Session Summary Question: Comments on the additional data presented at EASL regarding liver fat reduction - Management confirmed that the subgroup analysis did not change the powering assumptions for the VOYAGE study, focusing on overall assessments [29] Question: Challenges with enrollment and COVID-19 impact - Management acknowledged the difficulties but remains confident in completing enrollment as planned, despite the ongoing pandemic [35] Question: Timeline for presenting additional data from the Phase 2a study - Management indicated that there are no plans for additional data presentations this year, but a manuscript is in preparation [39] Question: Regulatory pathway for X-ALD and potential data timeline - Management expects to initiate a registration study for X-ALD in 2022, pending successful Phase 1 results [71] Question: Expectations for lower dose efficacy in VOYAGE study - Management explained that lower doses were included to better understand the dose-response relationship, with expectations for efficacy at higher doses [64] Question: Treatment protocols for patients testing positive for COVID during the trial - Management stated that COVID-19 would be treated like any other illness that could lead to withdrawal from the study [52] Question: Plans for targeting patients with cerebral involvement in X-ALD - Management confirmed that the current focus is on adult males with AMN, excluding those with cerebral involvement for the time being [92]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37355 VIKING THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 46-1073877 (State or other j ...